{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:19:23Z","timestamp":1792210763877,"version":"4.4.0"},"reference-count":21,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2014,10,22]],"date-time":"2014-10-22T00:00:00Z","timestamp":1413936000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2015,1]]},"abstract":"Summary<\/jats:title>\n \n Background<\/jats:title>\n \n Rifaximin therapy reduced risk of hepatic encephalopathy (\n HE<\/jats:styled-content>\n ) recurrence and\n HE<\/jats:styled-content>\n \u2010related hospitalisations during a 6\u2010month, randomised, placebo\u2010controlled trial (\n RCT<\/jats:styled-content>\n ) and a 24\u2010month open\u2010label maintenance (\n OLM<\/jats:styled-content>\n ) study. However, the impact of crossover from placebo to rifaximin therapy is unclear.\n <\/jats:p>\n <\/jats:sec>\n \n Aim<\/jats:title>\n \n To study the impact of crossing over from placebo to rifaximin treatment on breakthrough\n HE<\/jats:styled-content>\n and hospitalisation rates using a within\u2010subjects design.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n Adults with cirrhosis and history of overt\n HE<\/jats:styled-content>\n episodes, currently in\n HE<\/jats:styled-content>\n remission, received placebo during the\n RCT<\/jats:styled-content>\n and crossed over to rifaximin 550\u00a0mg twice daily during the\n OLM<\/jats:styled-content>\n study. Rate of breakthrough overt\n HE<\/jats:styled-content>\n episodes, hospitalisations and incidence and rate of adverse events (\n AE<\/jats:styled-content>\n s) were analysed during\n RCT<\/jats:styled-content>\n and first 6\u00a0months of\n OLM<\/jats:styled-content>\n .\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of 82 patients randomised to placebo in the\n RCT<\/jats:styled-content>\n who crossed over to the\n OLM<\/jats:styled-content>\n study, 39 experienced an\n HE<\/jats:styled-content>\n episode during the\n RCT<\/jats:styled-content>\n compared with 14 during the\n OLM<\/jats:styled-content>\n study (\n P\u00a0<\/jats:italic>\n <\n \u00a0<\/jats:italic>\n 0.0001). Significantly lower rates of\n HE<\/jats:styled-content>\n events were observed with rifaximin treatment compared with placebo treatment (\n P\u00a0<\/jats:italic>\n <\n \u00a0<\/jats:italic>\n 0.0001). Rates of\n HE<\/jats:styled-content>\n \u2010related hospitalisation were numerically lower during rifaximin treatment compared with placebo treatment, although not significant. Rates of most common\n AE<\/jats:styled-content>\n s, serious\n AE<\/jats:styled-content>\n s and infection\u2010related\n AE<\/jats:styled-content>\n s were similar between the two treatments.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n This analysis confirms the repeatability of results from the\n RCT<\/jats:styled-content>\n on safety and efficacy of rifaximin 550\u00a0mg twice daily in reducing the risk of hepatic encephalopathy recurrence, and suggests these findings are translatable outside of a rigorous, controlled trial setting.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/apt.12993","type":"journal-article","created":{"date-parts":[[2014,10,22]],"date-time":"2014-10-22T20:31:46Z","timestamp":1414009906000},"page":"39-45","source":"Crossref","is-referenced-by-count":50,"title":["Prolonged remission from hepatic encephalopathy with rifaximin: results of a placebo crossover analysis"],"prefix":"10.1111","volume":"41","author":[{"given":"J. S.","family":"Bajaj","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Hepatology and Nutrition Virginia Commonwealth University and McGuire VA Medical Center Richmond VA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. C.","family":"Barrett","sequence":"additional","affiliation":[{"name":"Salix Pharmaceuticals., Inc Raleigh NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Bortey","sequence":"additional","affiliation":[{"name":"Salix Pharmaceuticals., Inc Raleigh NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Paterson","sequence":"additional","affiliation":[{"name":"Salix Pharmaceuticals., Inc Raleigh NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. P.","family":"Forbes","sequence":"additional","affiliation":[{"name":"Salix Pharmaceuticals., Inc Raleigh NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,10,22]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.31250"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04590.x"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2012.05.016"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1024784327783"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.157"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(99)80144-5"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/lt.21129"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-984576"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe1000850"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-005-5089-0"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0b013e3283417567"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2012.03.009"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2009.04211.x"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907893"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04808.x"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.12.021"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-006-9442-4"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12070"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199549030-00009"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn078"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/cld.169"}],"container-title":["Alimentary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fapt.12993","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.12993","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T10:48:09Z","timestamp":1696502889000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.12993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,22]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["10.1111\/apt.12993"],"URL":"https:\/\/doi.org\/10.1111\/apt.12993","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.723874139.793535962","asserted-by":"object"}]},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,22]]}}}